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Purpose: To evaluate the safety, pharmacological effect and mechanism of action of an antifibrotic 
compound, safironil (SAF)/praziquantel (PZQ) combination on reversal of liver fibrogenesis in chronic 
murine Schistosomiasis mansoni. 
Methods: The antifibrotic effect of 0.5, 1 and 2 mg/ml of SAF was evaluated in vitro myofibroblast cell 
culture, using RNAse protection assay for collagen I mRNA expression and quantitative immunoblot for 
smooth muscle α-actin protein extract. Ninety Swiss albino mice were infected with 50 Schistosoma 
mansoni cercariae. SAF was provided in drinking water at a concentration of 1.5 mg/ml while 
praziquantel (PZQ) was given by gavage in a dose of 500 mg/kg. Mice, divided into five groups: infected 
non-treated; infected and PZQ-treated; infected PZQ- and SAF-treated; infected and SAF-treated; and 
control. After sacrificing the animals, the liver of each mouse was taken, weighed and used for 
histopathological examination, hydroxyproline assay and collagen determination.  
Results: SAF prevented myofibroblast activation at the pre-transcriptional level in a dose-dependent 
manner as monitored by collagen I mRNA levels  (expression reduced by 40, 70 and 90 % at doses of 
0.5, 1 and 2 mg/ml, respectively) or by smooth muscle α-actin (expression reduced by 70, 85 and 95 %, 
respectively). SAF decreased the production of collagen I by 60 % and laminin by 55 % but increased 
collagen III by 50 % relative to control. SAF had no effect on liver granuloma size and did not alter total 
hydroxyproline but altered the pattern of fibrosis by increasing collagen III and decreasing collagen I 
deposition. The most significant reduction in liver fibrosis was noticed in mice treated with SAF 
combined with PZQ. No toxic pharmacological effect was noticed during SAF treatment. 
Conclusion: When SAF was combined with PZQ, augmented reduction of liver fibrogenesis was 
achieved. The mechanism is probably through inhibition of new liver injury induced by parasite egg 
deposition and interruption of collagen type I synthesis with attenuation of pre-existent collagen.. 
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INTRODUCTION 
 
Hepatic fibrosis is a common response to 
various insults to the liver such as parasitic 
infection, chronic viral infection, autoimmune 
diseases, and hereditary and toxic damage 
[1]. Hepatic stellate cells (HSC) plays a 
crucial role during liver fibrosis. After 
hepatocyte damage, the cell becomes 
activated and starts to proliferate, during 
which it transforms from a resting vitamin A-
storing cell into an activated myofibroblast 
(MF)-like cell. Activated HSCs produce 
excessive amounts of extracellular matrix 
(ECM) compounds and inhibitors of matrix 
degredation. Therefore, this cell type is a key 
player in the fibrogenic response that may 
eventually lead to liver cirrhosis with 
subsequent hepatic fibrosis [2].  
 
In schistosomiasis, healing of parasite egg-
induced liver granuloma can lead to periportal 
fibrosis, and bleeding esophageal varices. 
Fibrogenesis is a dynamic potentially 
reversible process mediated through 
immunological responses to parasite eggs 
trapped in the liver… Collagen synthesis 
(especially type I) is quantitatively prominent 
and has been a target for therapeutic 
strategies against fibrosis [3]. A continuous 
murine cell line (GRX), has been obtained 
from fibrotic granulomas in mice liver 
experimentally infected with S. mansoni [4]. 
These cells display simultaneous 
characteristics of myofibroblasts and HSC. 
GRX cell line excretes ECM molecules such 
as collagen I, collagen III and fibronectin. 
Thus, it is regarded as a culture model of the 
wound healing response [5].  
 
HOE 077 [pyridine-2, 4-dicarboxylic-di (2-
methoxyethyl) amide] and its congener, 
safironil (SAF), represent a new class of anti-
collagen compounds designed as competitive 
inhibitor of propyl-4-hydroxylase [6]. This 
enzyme is essential for the formation of a 
stable collagen trimmer [7]. All general 
inhibitors of collagen, however, have potential 
for compromising the integrity of collagen-rich 
tissues such as skin, bone, and vasculature. 
SAF is an inactive pro-drug obtained by 
amidation of its carboxyl group. Its 
conversion to the active form requires 
oxidative deamidation, a function performed 
by the cytochrome P-450 family of heme 
proteins. This requirement confers a 
considerable degree of liver specificity, in that 
the concentration of cytochrome P-450 is far 
greater in liver than in other tissues. It has 
been reported that HOE 077 blocks 
production of collagen by hepatocytes in 
culture [8].  
 
The goal of this study was to assess the 
pharmacological effect of SAF on the 
activation of GRX and its production of ECM 
compounds in cell culture, as well as to 
investigate the pharmacological effect of SAF 
augmented with PZQ on reversal of liver 





Cell line and culture 
 
C3/HeN mice continuous cell line (GRX) was 
generously provided by Dr(Borojevic R), 
Instituto de Quimica, Rio de Janeiro, Brazil. 
Cultures were maintained in Dulbecco's 
Modified Essential Medium with 10% fetal 
bovine serum, 3 µg/ml of HEPES buffer, 1% 
penicillin and streptomycin. Cells were 
cultured at a concentration of 2 x 105 
cells/well in a total volume of 3 ml using Lab-
Tek tissue culture chambers slides (Miles, 
Naperville, IL). The cells were stimulated in 
vitro for morphological phenotype transfor-
mation and matrix proteins excretion by 
adding transforming growth factor β1 (TGFB1) 
monoclonal antibody (MAb), at 0.1 ng/ml. Its 
salient features include de novo production of 
smooth muscle α-actin as well as markedly 
increased expression of collagen I. 
 
In vitro analytical procedures and toxicity 
studies 
 
Total RNA was extracted from the cultured 
cells using TRIzol reagent according to the 
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manufacturer's instructions (Gibco BRL, life 
Technologies, Rockville, MD). RNase 
protection assay was performed using 
RiboQuant TM Multi-probe RNase Protection 
Assay System with the mCK-1 including 
mouse collagen (α-1) type I, multiprobe 
template sets (Pharmingen, San Diego, CA). 
Radioactivity was quantified by 32P imaging 
on a Storm-680 scanner and data analyzed 
using image QuantTM version 1.11 (Molecular 
Dynamics, Sunnyvale, CA). The smooth 
muscle isoform of α-actin was measured by 
quantitative western blot of extracts from 
cultured cells, as described by [9] and equal 
amounts of protein extract were loaded. 
Studies with cultures were replicated with at 
least three cell preparations. Synthesis of 
collagen was assayed as incorporation of [3H] 
proline into protein digestible by highly 
purified collagenase, as described by [10]. 
Before testing the effect of SAF on GRX cell 
activation in culture, toxicity studies were 
performed judged by cell detachment from 
the substratum after heparinization followed 
by iodine radioactive scintillation cell 
counting, trypan blue staining for cell viability 
or cellular lactate dehydrogenase to the 
medium. 
 
Animals and parasite Infection  
 
Six-week-old female, Swiss albino mice, 
weighing 16 - 18 g each, were purchased 
from Theodor Bilharz Research Institute 
TBRI, Egypt. Parasite infection was done 
through subcutaneous injection of 50 S. 
mansoni cercariae into each mouse. 
Approval of the institutional ethical committee 
for animal studies was obtained and the sudy 
followed the Office of Environmental Health 
and Radiation Safety, ACUC Protocol # 
1096-5. The animals were maintained 
according to accepted standards of animal 
care. The animals were housed in 
polypropline cages at 25 ± 2 oC and fed with 
standard pellet diet and water [11].  
 
 
Treatment of animals 
 
SAF was obtained in vials from Hoechst 
Company, Aktiengesellschaft, Frankfurt, 
Germany, and stored at 4oC. It was 
administered by gavage in drinking water at a 
concentration of 1.5 mg/ml from the 3rd to the 
6th month post-infection (p.i.). Control groups 
were given normal saline. PZQ was available 
as biltricide 600 mg tablets from Bayer 
Company. It was emulsified with 30 % 
glycerol prior to its use and given at 12 week 
p.i. at a dose of 500 mg/kg/dose. The dose 
was followed by another dose 9 days later to 
ensure the death of all eggs in the tissue. The 
mice were divided into 5 groups of 20 mice 
each. Group 1 mice served as positive 
control (infected, non-treated). Group 2 
received PZQ (infected and PZQ-treated). 
Group 3 received SAF and PZQ (infected, 
PZQ and SAF-treated). Group 4 received 
SAF alone (infected and SAF-treated). Group 
5 was negative control (non-infected, non-
treated). Ten mice from Groups I, II, III and IV 
were sacrificed at the 20th week p.i. The 
remaining mice from all the groups were 
sacrificed at the 24th week p.i. After sacrifice, 
the liver of each mouse was taken, weighed 
and divided into 3 portions; one part was 
used for tissue digestion, the second was 
preserved in 10 % formol saline for 
histopathological examination while the third 
portion was kept frozen at -70 oC for 
hydroxyproline assay and collagen 
determination. 
 
Parasitological, biochemical and liver 
function assays  
 
 For egg counting in the liver, fragments of 
liver tissue were weighed and left in 0.5% 
potassium hydroxide solution for digestion 
and counting of S. mansoni eggs according 
to the method of Cheever [12]. Briefly, 4 g of 
liver was shaking vigorously in a graduated 
flask with 0.1 KOH solution, shaken 
vigorously, allowed to stand for 24 h, shaken 
again, and 0.15 ml of the specimen placed on 
a glass slide for egg count. The results are 
expressed as the number of eggs/g liver 
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tissue. Collagen formation was estimated by 
total proline and hydroxyproline content of 
each individual liver using L-azetidine 2-
carboxylic acid as an internal standard. 
Following derivatization with 4-chloro-7-
nitrobenzofurazan, the components were 
analyzed using Programmable Solvent 
Module 126 columns, 4.6 x 75 mm and 
Gynkotek fluorescence detector FR-530 as 
described by Palmerini et al [13]. Before 
animal sacrifice, heparinized blood was 
collected by heart-puncture and plasma 
levels for analine aminotrasferase (ALT) and 
aspartate aminotransferase (AST) were 
measured using mice kits, according to 
routine clinical chemical methods 
(Department of Clinical Chemistry, Maternity 
and Children Hospital, Madina Munawarah, 
KSA)  
 
Histopathological and immunofluorescence 
staining studies 
 
 Liver biopsy specimens were fixed in 10 % 
formol saline, dehydrated and embedded in 
paraffin. Sections (4 µm thick) were stained 
with haematoxylin and eosin for 
histopathological examination. Measurement 
of granuloma size was carried out using a 
light microscope fitted with an ocular 
micrometer lens . The mean diameter of each 
granuloma was obtained by measuring two 
perpendicular diameters. For each section, 
ten granulomas were measured and the 
mean diameter of all lesions then calculated 
using the method described by Jacobs et al 
[14]. Semi-quantitation of collagen isotypes I 
and III was carried out as described by Gabr 
et al [15]. Briefly, the frozen liver sections 
were stained with the corresponding FITC 
conjugated MAb for 45 min at 4 oC and the 
intensity of the fluorescence measured by an 




This was carried out using SPSS, version 8.0 
software. Statistical significance was 
determined using one-way analysis of 
variance (ANOVA) and Student t-test. P < 




In vitro data 
 
No toxic effect of SAF was seen on cell 
culture at concentrations up to 2 mg/ml, as 
judged by cell detachment from the 
substratum, trypan blue staining, or leakage 
of cellular lactate dehydrogenase to the 
medium. SAF reduced expression of mRNA 
for type I collagen in a dose-dependent 
manner by 40, 70 and 90 % at doses of 0.5, 1 
and 2 mg/ml, respectively (Table 1). To 
exclude the possibility that SAF was acting 
selectively on collagen I expression, an 
independent parameter of cell culture 
activation, smooth muscle α-actin (which is a  
 
Table 1: GRX primary cell culture collagen I 
mRNA evaluated by RNAse protection assay 
 
SAF (mg/ml) cell 
culture on day 2 








*Data expressed relative to control cells, set at 
100 % (n = 4, p > 0.05) 
 
Table 2: GRX primary cell culture expression of 
smooth α-actin prepared and analyzed by 
quatitative immunoblot 
 
SAF (mg/ml) cell culture 
on day 5 
*Relative change 









*data expressed relative to control cell, set at 
100% (n =4), p > 0.05 
 
good marker for myofibroblast activation), 
was also monitored. SAF reduced the 
expression of this protein in a dose-
dependent manner by 70, 85 and 97 % at 
doses of 0.5, 1 and 2 mg/ml, respectively 
(Table 2). SAF increased the production of 
type III collagen and decreased the 
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production of type I collagen by the primary 
cultured myofibroblast cells (Fig 1). 
 
Figure 1: Effect of Safironil on matrix protein 
production of primary cell culture after 5 days 
activation 
 
In vivo data 
 
The results of parasitological assay of 
antifibrotic efficacy of safironil including liver 
weight and egg count/g liver tissue are 
presented in Table 3. The results of 
biochemical assay of hepatic hydroxyproline 
and collagen contents are shown in Table 4.  
The safety of safironil animal treatment on 
hepatic injury and hepatocytes damage was 
assessed by measuring serum levels of ALT 
and AST. No significant difference in serum 
levels of ALT was noticed between treated 
Groups, but AST level was higher in PZQ-
treated mice compared to other Groups as 




Prolonged liver injury results in hepatocyte 
damage, which triggers HSC activation and 
recruitment of inflammatory cells into the 
liver. HSC play a critical role in fibrogenesis. 
They produce collagen type I and secrete 
pro-fibrogenic cytokines and inhibitors of 
matrix-degrading enzymes (tissue inhibitor of 
matrix metalloproteinase) (MMP), causing the 
production of extracellular matrix deposition 
[16]. Hepatic fibrosis is historically thought to 
be a passive and irreversible process. 
However, results from many studies suggest 
that this process can be reversed, including 
the apoptosis of activated HSC. Thus, HSC is 
a ready target for antifibrotic therapy [17].  
 




Number of mice Weight of liver (g) 
(mean ± SD) 
Egg count/g liver 
tissue 
(mean ± SD) 
Size of granuloma (µm) 
(mean ± SD) 
 Week 20 Week 24 Week 20 Week 24 Week 20 Week 24 Week 20 Week 24 
1 10 7 1.9 ± 0.4 1.8 ± 0.3 3250± 413 3365 ± 356 642.9 ± 26.5 516.6 ± 17.1 
2 9 8 1.4± 0.9* 1.3± 0.2* 352± 270* 249 ± 240* 470.5 ± 25.1* 390.7 ± 19.1* 
3 10 7 1.3± 0.1* 1.2± 0.1* 333± 260* 210 ± 280* 391.2 ± 21.8** 220.6 ± 18.7** 
4 9 7 1.7 ± 0.3 1.6 ± 0.2 2951± 391 2918 ± 376 567.4 ± 26.5 412.3 ± 17.1 
5 10 - 1.2 ±  0.1 - - - - - 
 *Significantly different compared to Groups 1 and 4 (p ≤ 0.05); **significant different compared to Groups 
1, 2 and 4 (p ≤ 0.05) 
 
Table 4: Hydroxyproline and total collagen contents of mice liver (mean ± SD) 
 
Group Liver hydroxyproline (mg/g wet weight) Calculated collagen (mg/g wetweight) 
 Week 20 Week 24 Week 20 Week 24 
1 0.51 ± 0.21 0.66 ±0.19 4.1 ± 1.75 5.2 ± 1.39 
2 0.48 ±0.18* 0.61 ± 0.14* 2.58 ± 1.29* 3.1 ±1.23* 
3 0.44±0.13* 0.51 ± 0.13* 2.42 ±0.9* 1.89 ±0.8*1 
4 0.46 ± 0.2** 0.59 ±0.18** 3.51 ± 1.43** 2.61 ±1.41** 
5 0.21 ± 0.1 0.21 ± 0.1 1.3 ± 0.82 1.3 ± 0.82 
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*Significantly different in relation to Groups 1 and 4 (p ≤ 0.05) **Significantly different in relation to Group 1 
(p ≤ 0.05) 
Table 5: Effect of drugs animals treatment on 
hepatocyte markers ALT and AST 
 
Group ALT (U/L) AST (U/L) 
1 90.5 ± 8.8 200.8 ± 45.8 
2 116.8 ±10.5 314.5 ± 33.1* 
3 107.8 ± 9.7 294.4 ± 41.2 
4 99.8 ± 9.5 226.6 ± 34.9 
5 40 ± 0.2 35.1 ± 0.1 
*Significantly different compared to other treated 
Groups (p < 0.05) 
 
Several lines of therapy have been directed 
at the reduction of liver collagen formation. 
However, none has yielded satisfactory 
results [18].   
 
Steroids have been used as inhibitors of 
prolyl hydroxylase and anti-inflammatory 
agents [19] while praziquantel has been used 
as an antifibrotic drug. It acts by eliminating 
antigen source, but interrupts immune 
modulation, thereby causing poor scar 
absorption in the liver [20]. Colchicine is a 
microtubular disruptive drug but owing to its 
side effects, its use as a long term therapy 
has not been widely approved [21]. 
Halofuginone, the synthetic compound of a 
natural product, dichroa febrifuga Lour, has 
been evaluated as an antifibrotic agent in rat 
hepatic stellate cells [22]. However, it has 
been reported that the compound worsened 
liver fibrosis in bile duct-obstructed rats [23].  
 
The animals studies revealed that fibrosis 
process is reversible. Liver can undergo 
regression of fibrosis after withdrawal of the 
damaging stimulus, even in an advanced 
stage of cirrhosis [24]. In our studies, before 
testing the effect of safironil on GRX cell 
culture activation, toxicity studies were 
performed. No toxic effect of SAF was seen 
at concentrations up to 2 mg/ml. These 
findings are similar to those reported 
previously for hepatocytes in primary culture 
[8]. Our studies provide direct evidence that 
the antifibrinogenic effect of SAF involves 
down-regulation of cell culture activation. The 
specificity of safironil for the liver in chronic 
Schistosomiasis mansoni infection is believed 
to reflect a requirement for conversion of the 
pro-drug to an active inhibitor, a process in 
which the liver plays a pre-eminent role 
because of its high concentration of 
cytochrome P-450. In retrospect, it 
appearsthat the effect of safironil is targeted 
at myofibroblast responses to wound repair. 
The combination of anti-schistosomal drug 
and safironil led to the most profound 
reduction in liver granuloma size, while in 
immune fluorescence specimens, there was 
resolution of collagen fibers in treated mice 





We have demonstrated that the safironil 
reduces fibrogenesis in liver insult caused by 
S. mansoni egg deposition through inhibition 
of HSC activation. As such, it targets 
inflammation and wound repair and mitigates 
concern for the potential side effects of direct 
inhibitors of collagen protein synthesis. This 
raises the interesting possibility that a 
compound such as safironil may target 
wound repair beyond the liver and has a 
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